Cited by 338Glioma Diagnosis and TreatmentOptical Imaging and Spectroscopy TechniquesPhotodynamic Therapy Research Studies

The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index.

5-ALA and FDA approval for glioma surgery

Open access
Hadjipanayis, Constantinos G., Stummer, Walter·2019·Journal of Neuro-Oncology

Abstract

The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan®; photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017. This was the first ever optical imaging agent approved as an adjunct for the visualization of malignant tissue during surgery for brain tumors. The approval occurred a decade after European approval and a multicenter, phase III randomized trial which confirmed that surgeons using 5-ALA fluorescence-guided surgery as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery. Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. We chronicle the challenges encountered during the US FDA approval process to highlight a new standard for approval of intraoperative optical imaging agents in brain tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11060-019-03098-y

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. Administration USFaD (2006) FDA workshop brain cancer end-points

Cited by

Sorted by citations

Items 201–300 of 338

Metadata

Authors
Hadjipanayis, C. G., & Stummer, W.
Affiliations
University Hospital Münster (DE)
Venue
Journal of Neuro-Oncology
Published
2019-01-14
Volume
141
Issue
3
Pages
479-486
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2910072132
Cited by
338
References
59
Citations by year
2026: 19 · 2025: 53 · 2024: 60 · 2023: 51 · 2022: 59 · 2021: 52 · 2020: 32 · 2019: 12
FWCI
4.75
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuro-Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Merck
  • Novocure
  • Arbor Pharmaceuticals
  • National Cancer Institute (R01CA176659)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
Keywords
5-aminolevulinic acid, fluorescence-guided surgery, high-grade glioma, FDA drug approval, brain tumor surgery, tumor resection completeness, regulatory challenges
MeSH terms
Aminolevulinic Acid, Brain Neoplasms, Fluorescent Dyes, Glioma, Humans, United States, United States Food and Drug Administration, Drug Approval, Surgery, Computer-Assisted, Optical Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review